Cytotoxic T cells and neutralizing antibodies induced in rhesus monkeys by virus-like particle HIV vaccines in the absence of protection from SHIV infection

Virology

Volumn 245, Issue 1, 1998, Pages 65-74

  Wagner, Ralf ^b   Teeuwsen, Vera J P ^a   Deml, Ludwig ^b   Notka, Frank ^b   Haaksma, Anthonius G M ^a   Jhagjhoorsingh, Sunita S ^a   Niphuis, Henk ^a   Wolf, Hans ^b   Heeney, Jonathan L ^a  

^a BIOMEDICAL PRIMATE RESEARCH CENTRE   (Netherlands)

^b UNIVERSITY OF REGENSBURG   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIGEN P24; CONCANAVALIN A; GAG PROTEIN; GLYCOPROTEIN GP 120; HUMAN IMMUNODEFICIENCY VIRUS VACCINE; INTERLEUKIN 2; NEUTRALIZING ANTIBODY; POL PROTEIN;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CONTROLLED STUDY; CYTOTOXIC T LYMPHOCYTE; ENZYME LINKED IMMUNOSORBENT ASSAY; HUMAN IMMUNODEFICIENCY VIRUS; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; HUMORAL IMMUNITY; IMMUNIZATION; INTRAMUSCULAR DRUG ADMINISTRATION; MONONUCLEAR CELL; NONHUMAN; PRIORITY JOURNAL; RHESUS MONKEY; SIMIAN IMMUNODEFICIENCY VIRUS; VIRUS ISOLATION; VIRUS PARTICLE;

ANIMALIA; HUMAN IMMUNODEFICIENCY VIRUS; HUMAN IMMUNODEFICIENCY VIRUS 1; MACACA MULATTA; RNA VIRUSES; SIMIAE; SIMIAN IMMUNODEFICIENCY VIRUS; SIMIAN-HUMAN IMMUNODEFICIENCY VIRUS;

EID: 0032565726     PISSN: 00426822     EISSN: None     Source Type: Journal    
DOI: 10.1006/viro.1998.9104     Document Type: Article

References (46)

1. Baier M., Werner A., Bannert N., Metzner K., Kurth R. HIV suppression by interleukine-16. Nature. 378:1995;563.
2. Berman P. W., Gregory T. J., Riddle L., Nakamura G. R., Champe M. A., Porter J. P., Wurm F. M., Hershberg R. D., Cobb E. K., Eichberg J. W. Protection of chimpanzees from infection by HIV-1 after vaccination with recombinant glycoprotein gp120 but not gp160. Nature. 345:1990;622-625.
3. Borrow P., Lewicki H., Hahn B. H., Shaw G. M., Oldstone M. B. A. Virus-specific CD8+ cytotoxic T-lymphocyte activity associated with control of viremia in primary human immunodeficiency virus type 1 infection. J. Virol. 68:1994;6103-6110.
4. Bourgault I., Chirat F., Tartar A., Lévy J., Guillet J. G., Venet A. Simian immunodeficiency virus as a model for vaccination against HIV. Induction in rhesus macaques ofGAGNEF. J. Immunol. 152:1994;2530-2537.
5. Bourgault I., Villefroy P., Beyer C., Aubertin A.-M., Levy J. P., Venet A. Cytotoxic T-cell response and AIDS free survival in Simian Immunodeficiency Virus infected macaques. AIDS. 7:1993;S73-S79.
6. Bruck C., Thiriart C., Fabry L., Francotte M., Pala P., Opstal van O., Culp J., Rosenberg M., Wilde de M., Heidt P., Heeney J. L. HIV-1 envelope elicited neutralizing antibody titers correlate with protection and virus load in chimpanzees. Vaccine. 12:1994;1141-1148.
7. Carmichael A., Jin X., Sisson P., Borysiewicz L. Quantitative analysis of the Human Immunodeficiency Virus type 1 (HIV-1)-specific cytotoxic T lymphocyte response at different stages of HIV-1 infection: Differential CTL responses to HIV-1 and Epstein-Barr virus in late disease. J. Exp. Med. 177:1993;249-256.
8. Cocchi F., DeVico A. L., Garzino-Demo A., Arya S. K., Gallo R. C., Lusso P. Identification of RANTES, MIP-1α and MIP-1β as the major HIV-suppressive factors produced by CD8+ T cells. Science. 270:1995;1811-1815.
9. Deml L., Kratochwil G., Osterrieder N., Knuchel R., Wolf H., Wagner R. Increased incorporation of chimeric human immunodeficiency virus type 1 gp120 proteins into Pr55gag virus-like particles by an Epstein-Barr virus gp220/350-derived transmembrane domain. Virology. 235:1997a;10-25.
10. Deml L., Schirmbeck R., Reimann J., Wolf H., Wagner R. Recombinant human immunodeficiency Pr55gag virus-like particles presenting chimeric envelope glycoproteins induce cytotoxic T-cells and neutralizing antibodies. Virology. 235:1997b;26-39.
11. Deres K., Schild H., Wiesmüller K., Jung G., Rammensee H. In vivo. Nature. 342:1989;561-564.
12. Gallimore A., Cranage M., Cook N., Almond N., Bootman J., Rud E., Silvera P., Dennis M., Corcoran T., Stott J., McMichael A., Gotch F. Early suppression of SIV replication by CD8+nef. Nature Med. 1:1995;1167-1173.
13. Gheysen D., Jacobs E., de Foresta F., Thiriart C., Francotte M., Thines D., De Wilde M. Assembly and release of HIV-1 precursor Pr55gag virus-like particles from recombinant baculovirus-infected insect cells. Cell. 59:1989;103-112.
14. Haaft ten P. J. F., Cornelissen M., Goudsmit J., Koornstra W. H., Dubbes R., Niphuis H., Peeters M., Thiriart C., Bruck C., Heeney J. L. Virus load in human immunodeficiency virus type 1-infected chimpanzees: Effect of pre-exposure vaccination. J. Gen. Virol. 76:1995;1015-1020.
15. Haffar O., Garrigues J., Travis B., Moran P., Zarling J., Hu S. L. Human immunodeficiency virus-like, nonreplicating particles assemble in a recombinant vaccinia virus expression system. J. Virol. 64:1990;2653-2659.
16. Haist S., Marz J., Wolf H., Modrow S. Reactivities of HIV-1 gag-derived peptides with antibodies of HIV-1-infected and uninfected humans. AIDS Res Hum Retrovirus. 8:1992;1909-1917.
17. Haynes B. F., Pantaleo G., Fauci A. S. Toward an understanding of the correlates of protective immunity to HIV infection. Science. 271:1996;324-328.
18. Heeney J. L., Bruck C., Goudsmit J., Montagnier L., Schultz A., Tyrrell D., Zolla-Pazner S. Immune correlates of protection from HIV infection and AIDS. Immunol. Today. 18:1997;4-8.
19. Heeney J. L., Els van C. A. C. M., Vries de P., Haaft ten P., Otting N., Koornstra W., Boes J., Dubbes R., Niphuis H., Dings M., Cranage M., Norley S., Jonker M., Bontrop R. E., Osterhaus A. Major histocompatibility complex class-I associated vaccine protection from Simian Immunodeficiency Virus infected peripheral blood cells. J. Exp. Med. 180:1994;769-774.
20. Hulskotte E. G. J., Geretti A.-M., Siebelink K. H. J., Amerongen G. v., Cranage M. P., Rud E. W., Norley S. G., Vries de P., Osterhaus A. D. M. E. Vaccine-induced virus-neutralizing antibodies and cytotoxic T cells do not protect macaques from experimental infection with Simian Immunodeficiency Virus SIVmac32H (J5). J. Virol. 69:1995;6289-6296.
21. Klein M. R., Baalen van C. A., Holwerda A. M., Kerkhof Garde S. R., Bende R. J., Keet I. P., Eeftinck-Schattenkerk J. K., Osterhaus A. D., Schuitemaker H., Miedema F. Kinetics of Gag-specific cytotoxic T lymphocyte responses during the clinical course of HIV-1 infection: A longitudinal analysis of rapid progressors and long-term asymptomatics. J. Exp. Med. 181:1995;1365-1372.
22. Koup R. A., Safrit J. T., Cao Y., Andrews A., McLeod G., Borkowsky W., Farthing C., Ho D. D. Temporal association of cellular immune responses with the initial control of viremia in primary human immunodeficiency virus type 1 syndrome. J. Virol. 68:1994;4650-4655.
23. Lehner T., Wang Y., Cranage M., Bergmeier L. A., Mitchell E., Tao L., Hall G., Dennis M., Cook N., Brookes R., Klavinskis L., Jones I., Doyle C., Ward R. Protective mucosal immunity elicited by targeted iliac lymph node immunization with a subunit SIV envelope and core vaccine in macaques. Nature Med. 2:1996;767-775.
24. Levy J. A. Pathogenesis of human immunodeficiency virus infection. Microbiol. Rev. 57:1993;183-289.
25. Li J., Lord C. I., Haseltine W., Letvin N. L., Sodroski J. Infection of cynomolgus monkeys with a chimeric HIV/SIVmac virus that expresses the HIV-1 envelope glycoprotein. J. Acquir. Immun. Defic. Syndr. 5:1992;639-646.
26. Lipford G. B., Wagner H., Heeg K. Vaccination with immunodominant peptides encapsulated in Quil A-containing liposomes induces peptide-specific primary CD8+ cytotoxic T cells. Vaccine. 12:1994;73-80.
27. Mackewicz C., Levy J. A. CD8+ cell anti-HIV activity: Nonlytic suppression of virus replication. AIDS Res. Hum. Retrovir. 8:1992;1039-1050.
28. Newman M. J., Wu J.-Y., Gardner B. H. Saponin adjuvant induction of ovalbumin-specific CD8+ cytotoxic T lymphocyte responses. J. Immunol. 148:1992;2357-2363.
29. Rinaldo, Huang X.-L., Fan Z., Ding M., Beltz L., Panicali A. D., Mazzara G., Liebmann J., Cottrill M., Gupta P. High levels of anti-human immunodeficiency virus type 1 (HIV-1) memory cytotoxic T-lymphocyte activity and low viral load are associated with lack of disease in HIV-1-infected long-term nonprogressors. J. Virol. 69:1995;5838-5842.
30. Safrit J. T., Andrews C. A., Zhu T., Ho D. D., Koup R. A. Characterization of Human Immunodeficiency virus type 1-specific cytotoxic T lymphocyte clones isolated during acute seroconversion: Recognition of autologous virus sequences within a conserved immunodominant epitope. J. Exp. Med. 1994;463-472.
31. Scalzo A. A., Elliott S. L., Cox J., Gardner J., Moss D. J., Suhrbier A. Induction of protective cytotoxic T cells to murine cytomegalovirus by using a nonapeptide and a human-compatible adjuvant (Montanide ISA 720). J. Virol. 69:1995;1306-1309.
32. Shioda T., Shibuta H. Production of human immunodeficiency virus (HIV)-like particles from cells infected with recombinant vaccinia viruses carrying the gag gene of HIV. Virology. 175:1990;139-148.
33. Smith A. J., Cho M. I., Hammarskjold M. L., Rekosh D. Human immunodeficiency virus type 1 Pr 55 gag and Pr 150 gagpol expressed from a simian virus 40 late replacement vector are efficiently processed and assembled into virus like particles. J. Virol. 64:1990;2743-2750.
34. Takahashi H., Cohen J., Hosmalin A., Cease K. B., Houghten R., Cornette J. L., DeLisi C., Moss B., Germain R. N., Berzofsky J. A. An immunodominant epitope of the human immunodeficiency virus envelope glycoprotein gp160 recognized by class I major histocompatibility complex molecule-restricted murine cytotoxic T lymphocytes. Proc. Natl. Acad. Sci. USA. 85:1988;3105-3109.
35. Venet A., Bourgault I., Aubertin A.-M., Kieny M.-P., Levy J. P. Cytotoxic T lymphocyte response against multiple Simian Immunodeficiency Virus (SIV) proteins in SIV-infected macaques. J. Immunol. 148:1992;2899-2908.
36. Voss G., Li J., Manson K., Wyand M., Sodroski J., Letvin N. L. Human Immunodeficiency Virus type 1 envelope glycoprotein-specific cytotoxic T lymphocytes in Simian-Human Immunodeficiency Virus-infected rhesus monkeys. Virology. 208:1995;770-775.
37. Wagner R., Boltz T., Deml L., Modrow S., Wolf H. Induction of cytolytic T lymphocytes directed towards the V3 loop of the human immunodeficiency virus type 1 external glycoprotein gp120 by p55gag/V3 chimeric vaccinia viruses. J. Gen. Virol. 74:1993;1261-1269.
38. Wagner R., Deml L., Fitzon T., Wolf H. Molecular Approaches to the Control of Infectious Diseases. 1995;Cold Spring Harbor Laboratory, Cold Spring Harbor.
39. Wagner R., Deml L., Fließbach H., Wanner G., Wolf H. Assembly and extracellular release of chimeric HIV-1 Pr55gag retrovirus-like particles. Virology. 200:1994;162-175.
40. Wagner R., Deml L., Schirmbeck R., Niedrig M., Reimann J., Wolf H. Construction, expression, and immunogenicity of chimeric HIV-1 virus-like particles. Virology. 220:1996;128-140.
41. Wagner R., Fließbach H., Wanner G., Motz M., Niedrig M., Deby G., Brunn von A., Wolf H. Studies on processing, particle formation, and immunogenicity of the HIV-1 gag gene product: a possible component of a HIV vaccine. Arch. Virol. 127:1992;117-137.
42. Walker C. M., Moody D. J., Stites D. P., Levy J. A. CD8+ lymphocytes can control HIV infectionin vitro. Science. 234:1986;1563-1566.
43. Wills J. W., Craven R. C. Form, function, and use of retroviral Gag proteins. AIDS. 5:1991;639-654.
44. Yasutomi Y., Koenig S., Woods R. M., Madsen J., Wassef N. A., Alving C. R., Klein H. J., T. E. N., Boots L. J., Kessler J. A., Emini E. A., Conley A. J., Letvin N. L. A vaccine-elicited single viral epitope-specific cytotoxic T lymphocyte response does not protect against intravenous cell-free Simian Imunodeficiency Virus challenge. J. Virol. 69:1995;2279-2284.
45. Yasutomi Y., Reimann K. A., Lord C. I., Miller M. D., Letvin N. L. Simian Immunodeficiency Virus-specific CD8+ lymphocyte response in acutely infected rhesus monkeys. J. Virol. 67:1993;1707-1711.
46. Zhou F., Rouse B. T., Huang L. Induction of cytotoxic T lymphocytesin vivo. J. Immunol. 149:1992;599-604.